Elevated Serum Levels of Advanced Glycation End Products and their Monocyte Receptors in Patients with Type 2 Diabetes

Archives of Medical Research

Volumn 42, Issue 7, 2011, Pages 596-601

  Su, Xu dong ^a   Li, Shou she ^a   Tian, Ya qiang ^a   Zhang, Zhao yan ^b   Zhang, Guang zhen ^a   Wang, Le xin ^c  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

^b Women and Children Hospital   (China)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Advanced glycation end products; Receptors of advanced glycation end products; Therapy; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION;

BASE SEQUENCE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84862923026     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.11.001     Document Type: Article

References (38)

1. Fox C.S., Larson M.G., Leip E.P., et al. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 2005, 28:2436-2440.
2. Cappellari A., Airaghi L., Capra R., et al. Early peripheral nerve abnormalities in impaired glucose tolerance. Electromyogr Clin Neurophysiol 2005, 45:241-244.
3. Haslbeck K.M., Schleicher E., Bierhaus A., et al. The AGE/RAGE/NF-(kappa) B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005, 113:288-291.
4. Singleton J.R., Smith A.G., Russell J.W., et al. Microvascular complications of impaired glucose tolerance. Diabetes 2003, 52:2867-2873.
5. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007, 24:137-144. Diabetes Prevention Program Research Group.
6. Vlassara H., Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep 2007, 7:235-241.
7. Negrean M., Stirban A., Stratmann B., et al. Effects of low- and high-advanced glycation end product meals on macro and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007, 85:1236-1243.
8. Uribarri J., Cai W., Peppa M., et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007, 62:427-433.
9. Koschinsky T., He C.J., Mitsuhashi T., et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997, 94:6474-6479.
10. Genuth S., Sun W., Cleary P., et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10 year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111.
11. Monnier V.M., Bautista O., Kenny D., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. Diabetes 1999, 48:870-880.
12. Hofmann S.M., Dong H.-J., Li Z., et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002, 51:2082-2089.
13. Sandu O., Song K., Cai W., et al. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005, 54:2314-2319.
14. Chen Y., Yan S., Colgan J., et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol 2004, 173:1399-1405.
15. Schmidt A.M., Yan S.D., Yan S.F., et al. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000, 1498:99-111.
16. Flyvbjerg A., Denner L., Schrijvers B.F., et al. Long-term renal effects of a neutralizing rage antibody in obese type 2 diabetic mice. Diabetes 2004, 53:166-172.
17. Bucciarelli L.G., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein e-null mice. Circulation 2002, 106:2827-2835.
18. Maillard-Lefebvre H., Boulanger E., Daroux M., et al. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology 2009, 48:1190-1196.
19. Raucci A., Cugusi S., Antonelli A., et al. A soluble form of the receptor for advanced glycation end products (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008, 22:3716-3727.
20. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
21. Yamagishi S., Nakamura K., Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPARgamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009, 60:174-178.
22. Takeuchi M., Makita Z., Bucala R., et al. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds invivo. Mol Med 2000, 6:114-125.
23. Tam X.H., Shiu S.W., Leng L., et al. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in type 2 diabetes. Clin Sci (Lond) 2011, 120:81-89.
24. Tahara N., Yamagishi S.I., Matsui T., et al. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. CardiovascTher 2010, 10.1111/j.1755-5922.2010.00177.x.
25. Unoki H., Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des 2008, 14:987-989.
26. Goldin A., Beckman J.A., Schmidt A.M., et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
27. Ilhan N., Halifeoglu I., Ozercan H.I., et al. Tissue malondialdehyde and adenosine triphosphatase level after experimental liver ischaemia-reperfusion damage. Cell Biochem Funct 2001, 19:207-212.
28. Parveen K., Khan M.R., Mujeeb M., et al. Protective effects of pycnogenol on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats. Chem Biol Interact 2010, 186:219-227.
29. Zhang Z., Liew C.W., Handy D.E., et al. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and β-cell apoptosis. FASEB J 2009, 24:1497-1505.
30. Lo M.C., Lu C.I., Chen M.H., et al. Glycoxidative stress-induced mitophagy modulates mitochondrial fates. Ann NY Acad Sci 2010, 1201:1-7.
31. Hou F.F., Ren H., Owen W.F., et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004, 15:1889-1896.
32. Zhang L., Postina R., Wang Y. Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease. Cell Mol Life Sci 2009, 66:3923-3935.
33. Norata G.D., Garlaschelli K., Grigore L., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009, 19:129-134.
34. Nakamura K., Adachi H., Matsui T., et al. Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism 2009, 58:421-425.
35. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
36. Uribarri J., Cai W., Ramdas M., et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011, 34:1610-1616.
37. Takeuchi M., Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008, 14:973-978.
38. Yamagishi S., Ueda S., Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007, 13:2832-2836.